SOURCE: Targeted Genetics

May 30, 2007 07:30 ET

Targeted Genetics to Report Interim Data From a Phase I/II Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis and Highlight AAV Development Platform in 9 Additional Abstracts at

ASGT Annual Meeting

SEATTLE, WA--(Marketwire - May 30, 2007) - Targeted Genetics Corporation (NASDAQ: TGEN) and its academic and corporate collaborators will report data in 10 oral and poster presentations, as well as Scientific and Media sessions, at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT), May 30 - June 3 in Seattle, Washington.

Philip J. Mease, M.D., clinical professor at the University of Washington School of Medicine, chief of rheumatology clinical research at the Swedish Medical Center, practicing physician with Seattle Rheumatology Associates and Targeted Genetics' Principal Investigator, will discuss interim safety and efficacy data from an ongoing Phase I/II clinical trial of tgAAC94 in patients with inflammatory arthritis. Additional presentations will highlight Targeted Genetics' collaborations in the areas of HIV/AIDS vaccines and Huntington's disease, as well as basic and applied AAV vector biology and production.

In addition, Barrie J. Carter, Ph.D., Executive Vice President and Chief Scientific Officer of Targeted Genetics, will present an "Industry Perspective on Recruitment of Subjects for Clinical Trials" at a Scientific Symposia round table discussion on the ethics of patient selection. Dr. Mease will present "Gene therapy as the next step in biotech development and the biologic therapeutic continuum" at a Media Session on the use of gene therapy to provide systemically circulating anti-TNF inhibitors to reduce signs and symptoms in patients with inflammatory arthritis.

"As a company committed to developing AAV-based therapies for diseases with significant unmet medical need, advancing both the scientific and the commercial potential of our programs is of great importance," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "These presentations at ASGT underscore the progress being made in our product development programs and in multiple areas of research. Our product development platform is built on a solid foundation of AAV biology, and we are pleased to share the advances that we and our collaborators have made in this area with the gene therapy community."

Presentations relevant to Targeted Genetics' product development programs are:

Interim Phase I/II data from an ongoing trial of tgAAC94 in patients with inflammatory arthritis:

Abstract #1053
"A Phase I/II Clinical Study of Intra-Articular Administration of a
Recombinant Adeno-Associated Vector Containing a TNF-alpha antagonist Gene
in Inflammatory Arthritis." Oral Presentation - Sunday, June 3.
HIV/AIDS Vaccines:
Abstract #87
"Development and Characterization of a Relative Potency Assay for rAAV1
Vectors for Use as Vaccines." Poster Presentation - Thursday, May 31.
Huntington's Disease/RNAi:
Abstract #57
"Viral Delivery of shRNAs as a Potential Therapy for Huntington's Disease."
Oral Presentation - Thursday, May 31.

Abstract #695
"In Vitro and In Vivo Evaluation of shRNAs and miRNA shuttles for
Therapeutic RNAi." Poster Presentation - Friday, June 1.

Abstract #724
"Convection-Enhanced Delivery (CED) of AAV1-hrGFP into the Monkey Brain
Results in Robust Neuronal and Non-Neuronal Transduction of Cortical and
Subcortical Regions." Oral Presentation - Saturday, June 2.
AAV Vector Biology and Production:
Abstract #84
"High Titer Adeno-Associated Viral Vector Production by a Vero-Derived
Producer Cell Line." Poster Presentation - Thursday, May 31.

Abstract #313
"Production of Ad/AAV-Hybrids Encoding Proteins That Inhibit Viral
Propagation." Poster Presentation - Thursday, May 31.

Abstract #385
"Nox2-Dependent Endosomal H2O2 Facilitates rAAV2 Infection by Activating
Capsid PLA2." Oral Presentation - Friday, June 1.

Abstract #719
"Biological Differences in rAAV Transduction of Human and Old World Non-
Human Primate Airway Epithelia." Oral Presentation - Saturday, June 2.

Abstract #848
"Hybrid Adeno-Associated Virus Bearing Nonhomologous Inverted Terminal
Repeats Enhances Dual=Vector Reconstruction of Minigenes In Vivo." Poster
Presentation - Saturday, June 2.
For more information about the 10th Annual Meeting of the American Society of Gene Therapy, please refer to www.asgt.org.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding presentations of clinical and preclinical data, the potential of our AAV development platform and other statements about our plans, objectives, intentions and expectations. These forward-looking statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of these forward-looking statements. Actual results or developments may be materially different from the results projected or implied in these forward-looking statements. Factors that could affect our actual results include, but are not limited to, the risk of preclinical results not advancing into clinical or therapeutic benefit, our ability to obtain, maintain and protect our intellectual property, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and, whether regulatory or institutional approvals can be obtained and maintained, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2006 as updated in its Form 10-Q for the quarter ended March 31, 2007. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change these expectations.

Contact Information

  • Investor and Media Contact:
    Stacie D. Byars
    Director, Communications
    Targeted Genetics Corporation
    (206) 521-7392